cohbar
antifibrotic
peptide
combination
nintedanib
shows
enhanced
effects
idiopathic
pulmonary
fibrosis
model
menlo
park
globe
newswire
cohbar
nasdaq
cwbr
clinical
stage
biotechnology
company
developing
mitochondria
based
therapeutics
treat
chronic
diseases
extend
healthy
lifespan
today
announced
new
preclinical
data
demonstrating
combination
analog
nintedanib
leading
standard
care
treatment
idiopathic
pulmonary
fibrosis
ipf
produced
enhanced
effects
compared
nintedanib
alone
mice
new
data
therapeutic
mouse
model
ipf
showed
treatment
combination
nintedanib
produced
greater
reductions
fibrosis
inflammation
cytokine
levels
collagen
deposition
new
data
provide
clear
evidence
unique
mechanism
action
cohbar
antifibrotic
peptides
potential
combined
effectively
existing
treatment
achieve
even
greater
effects
said
kenneth
cundy
phd
cohbar
chief
scientific
officer
previously
demonstrated
efficacy
analog
peptides
administered
alone
prevention
treatment
fibrosis
preclinical
models
ipf
compelling
data
supporting
clinical
potential
plan
present
data
upcoming
kol
meeting
continue
move
program
towards
final
selection
clinical
mouse
study
fibrosis
induced
intratracheal
administration
bleomycin
treatment
vehicle
placebo
nintedanib
combination
two
drugs
initiated
seven
days
later
fibrosis
established
days
treatment
resulting
effects
lung
fibrosis
inflammation
collagen
deposition
secretion
proinflammatory
cytokines
lung
fluid
measured
compared
nintedanib
alone
combination
nintedanib
produced
greater
reductions
ashcroft
lung
fibrosis
score
inflammation
collagen
secretion
deposition
secretion
key
cytokines
despite
current
availability
two
approved
drugs
nintedanib
pirfenidone
ipf
patients
still
dying
respiratory
failure
major
unmet
medical
need
better
treatments
stated
professor
toby
maher
director
interstitial
lung
disease
professor
medicine
keck
school
medicine
university
southern
california
anticipated
new
drug
ipf
used
conjunction
current
standard
care
exciting
new
preclinical
results
suggest
combination
cohbar
peptides
nintedanib
potential
achieve
enhanced
effects
ipf
details
new
data
available
cohbar
website
key
opinion
leader
webinar
ipf
cohbar
host
key
opinion
leader
webinar
current
treatment
landscape
ipf
unmet
medical
need
positive
findings
preclinical
studies
cohbar
analogs
friday
november
et
interested
parties
register
event
analogs
ipf
fibrotic
diseases
analog
peptides
modified
analogs
natural
peptide
sequence
encoded
mitochondrial
dna
data
efficacy
analog
peptides
preclinical
models
ipf
recently
presented
american
thoracic
society
virtual
annual
meeting
august
human
lung
cells
decreased
expression
key
fibrosis
biomarkers
including
alpha
smooth
muscle
actin
αsma
collagen
types
iii
also
decreased
transformation
healthy
lung
cells
fibrotic
cells
induction
resulting
reduced
production
fibrotic
components
αsma
alpha
vivo
decreased
lung
fibrosis
inflammation
prophylactic
mouse
model
ipf
initiating
treatment
peptide
immediately
fibrosis
induction
bleomycin
therapeutic
mouse
model
ipf
starting
peptide
treatment
one
week
induction
addition
using
exacting
therapeutic
model
ipf
two
new
analogs
significantly
reduced
lung
fibrosis
assessed
ashcroft
score
reduced
inflammation
decreased
changes
lung
weight
collagen
deposition
lung
tissue
collagen
secretion
lung
fluid
ipf
idiopathic
pulmonary
fibrosis
ipf
chronic
progressive
debilitating
usually
fatal
interstitial
lung
disease
affects
approximately
people
orphan
disease
results
scarring
lungs
also
known
fibrosis
two
approved
treatments
help
slow
progression
ipf
currently
treatment
stop
reverse
scarring
lung
average
patients
diagnosed
ipf
live
two
five
years
diagnosis
cohbar
cohbar
nasdaq
cwbr
clinical
stage
biotechnology
company
focused
research
development
mitochondria
based
therapeutics
emerging
class
drugs
treatment
chronic
diseases
mitochondria
based
therapeutics
originate
discovery
cohbar
founders
novel
group
naturally
occurring
peptide
sequences
within
mitochondrial
genome
shown
potential
regulate
key
processes
multiple
systems
organs
body
date
company
discovered
mitochondrial
derived
peptides
generated
analogs
cohbar
efforts
focus
development
peptides
therapeutics
offer
potential
address
broad
range
diseases
underlying
impact
mitochondrial
dysfunction
company
lead
compound
phase
stage
phase
clinical
trial
nash
obesity
addition
cohbar
four
preclinical
programs
analogs
fibrotic
diseases
analogs
associated
ards
analogs
cancer
orphan
diseases
analogs
cancer
immunotherapy
additional
company
information
please
visit
statements
news
release
contains
statements
historical
facts
within
meaning
private
securities
litigation
reform
act
statements
based
current
beliefs
expectations
assumptions
regarding
future
business
future
plans
strategies
projections
anticipated
events
future
conditions
cases
identify
statements
words
believe
may
estimate
continue
anticipate
intend
could
would
project
plan
expect
goal
seek
future
likely
negative
plural
words
similar
expressions
examples
statements
include
limited
statements
regarding
anticipated
outcomes
research
clinical
trials
mitochondria
based
therapeutic
mbt
candidates
expectations
regarding
growth
mbts
significant
future
class
drug
products
statements
regarding
anticipated
therapeutic
properties
potential
mitochondrial
peptide
analogs
mbts
potential
therapies
including
limited
treatment
ipf
cautioned
statements
guarantees
future
performance
actual
results
developments
may
differ
materially
set
forth
statements
factors
could
cause
actual
results
differ
materially
statements
include
ability
successfully
advance
drug
discovery
development
programs
including
delay
termination
ongoing
clinical
trials
possible
inability
mitigate
prevalence
persistence
injection
site
reactions
receipt
unfavorable
feedback
regulators
regarding
safety
tolerability
possibility
developments
affecting
viability
clinical
candidate
commercial
potential
results
different
earlier
data
results
including
less
favorable
may
support
clinical
development
ability
raise
additional
capital
necessary
continue
operations
ability
recruit
retain
key
management
scientific
personnel
risk
intellectual
property
may
adequately
protected
ability
establish
maintain
partnerships
corporate
industry
partners
risks
related
impact
business
pandemic
similar
public
health
crises
additional
assumptions
risks
uncertainties
described
detail
registration
statements
reports
filings
securities
exchange
commission
applicable
canadian
securities
regulators
available
website
cautioned
statements
guarantees
future
performance
actual
results
may
differ
materially
set
forth
statements
statements
information
contained
news
release
made
date
hereof
cohbar
undertake
obligation
update
publicly
revise
statements
information
whether
result
new
information
future
events
otherwise
unless
required
applicable
securities
laws
nothing
herein
shall
constitute
offer
sell
solicitation
offer
buy
securities
contacts
jordyn
tarazi
director
investor
relations
cohbar
joyce
allaire
lifesci
advisors
llc
jallaire
